High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases

Hepatology

Volumn 55, Issue 6, 2012, Pages 1863-1875

  Yan, Wei ^a   Chang, Ying ^a   Liang, Xiaoyan ^a   Cardinal, Jon S ^a   Huang, Hai ^a   Thorne, Stephen H ^a   Monga, Satdarshan P S ^a   Geller, David A ^a   Lotze, Michael T ^a   Tsung, Allan ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; TOLL LIKE RECEPTOR 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INVASION; CANCER MODEL; CARCINOMA CELL; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVATION; EXTRACELLULAR SPACE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN TISSUE; HYPOXIA; INFLAMMATION; LIVER CELL CARCINOMA; LUNG METASTASIS; MALE; METASTASIS; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CASPASE 1; CELL HYPOXIA; CELL LINE, TUMOR; ENZYME ACTIVATION; HMGB1 PROTEIN; HUMANS; INTERLEUKIN-1BETA; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 84861536618     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25572     Document Type: Article

References (35)

1. Rampone B, Schiavone B, Confuorto G. Current management of hepatocellular cancer. Curr Oncol Rep 2010; 12: 186-192.
2. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
3. Talwalkar JA, Gores GJ. Diagnosis and staging of hepatocellular carcinoma. Gastroenterology 2004; 127: S126-S132.
4. Lu SC, Mato JM. Role of methionine adenosyltransferase and S-adenosylmethionine in alcohol-associated liver cancer. Alcohol 2005; 35: 227-234.
5. Di Bisceglie AM, Simpson LH, Lotze MT, Hoofnagle JH. Development of hepatocellular carcinoma among patients with chronic liver disease due to hepatitis C viral infection. J Clin Gastroenterol 1994; 19: 222-226.
6. Di Bisceglie AM, Rustgi VK, Hoofnagle JH, Dusheiko GM, Lotze MT. NIH conference. Hepatocellular carcinoma. Ann Intern Med 1988; 108: 390-401.
7. Harrison L, Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy?. Oncologist 2004; 9(SUPPL 5): 31-40.
8. Finger EC, Giaccia AJ. Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metastasis Rev 2010; 29: 285-293.
9. Ding W, You H, Dang H, LeBlanc F, Galicia V, Lu SC, et al. Epithelial-to-mesenchymal transition of murine liver tumor cells promotes invasion. HEPATOLOGY 2010; 52: 945-953.
10. Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A, et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009; 15: 35-44.
11. Peinado H, Lavotshkin S, Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol 2011; 21: 139-146.
12. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010; 28: 367-388.
13. Tang D, Kang R, Zeh HJ, 3rd Lotze MT. High-mobility group box 1 and cancer. Biochim Biophys Acta 2010; 1799: 131-140.
14. Schroder K, Tschopp J. The inflammasomes. Cell 2010; 140: 821-832.
15. Carrascal MT, Mendoza L, Valcarcel M, Salado C, Egilegor E, Telleria N, et al. Interleukin-18 binding protein reduces b16 melanoma hepatic metastasis by neutralizing adhesiveness and growth factors of sinusoidal endothelium. Cancer Res 2003; 63: 491-497.
16. Okamoto M, Liu W, Luo Y, Tanaka A, Cai X, Norris DA, et al. Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta. J Biol Chem 2010; 285: 6477-6488.
17. Tsung A, Klune JR, Zhang X, Jeyabalan G, Cao Z, Peng X, et al. HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J Exp Med 2007; 204: 2913-2923.
18. Yan W, Fu Y, Tian D, Liao J, Liu M, Wang B, et al. PI3 kinase/Akt signaling mediates epithelial-mesenchymal transition in hypoxic hepatocellular carcinoma cells. Biochem Biophys Res Commun 2009; 382: 631-636.
19. Tang D, Lotze MT, Kang R, Zeh HJ. Apoptosis promotes early tumorigenesis. Oncogene 2010; 30: 1851-1854.
20. Jarnagin W, Chapman WC, Curley S, D'Angelica M, Rosen C, Dixon E, Nagorney D. Surgical treatment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford) 2010; 12: 302-310.
21. Cha C, Dematteo RP. Molecular mechanisms in hepatocellular carcinoma development. Best Pract Res Clin Gastroenterol 2005; 19: 25-37.
22. Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J, etal. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol 2001; 19: 3660-3668.
23. Yang D, Chen Q, Yang H, Tracey KJ, Bustin M, Oppenheim JJ. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol 2007; 81: 59-66.
24. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191-195.
25. Youn JH, Shin JS. Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion. J Immunol 2006; 177: 7889-7897.
26. Tang D, Kang R, Cheh CW, Livesey KM, Liang X, Schapiro NE, et al. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene 2010; 29: 5299-5310.
27. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5: 749-759.
28. Davis BK, Wen H, Ting JP. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol 2011; 29: 707-735.
29. Hu B, Elinav E, Huber S, Booth CJ, Strowig T, Jin C, et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci U S A 2010; 107: 21635-21640.
30. Yazdi AS, Drexler SK, Tschopp J. The role of the inflammasome in nonmyeloid cells. J Clin Immunol 2010; 30: 623-627.
31. Haybaeck J, Zeller N, Wolf MJ, Weber A, Wagner U, Kurrer MO, et al. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 2009; 16: 295-308.
32. Zhou RR, Zhao SS, Zou MX, Zhang P, Zhang BX, Dai XH, et al. HMGB1 cytoplasmic translocation in patients with acute liver failure. BMC Gastroenterol 2011; 11: 21.
33. Jung JH, Park JH, Jee MH, Keum SJ, Cho MS, Yoon SK, Jang SK. Hepatitis C virus infection is blocked by HMGB1 released from virus-infected cells. J Virol 2011; 85: 9359-9368.
34. DiNorcia J, Moroziewicz DN, Ippagunta N, Lee MK, Foster M, Rotterdam HZ, et al. RAGE signaling significantly impacts tumorigenesis and hepatic tumor growth in murine models of colorectal carcinoma. J Gastrointest Surg 2010; 14: 1680-1690.
35. Gong H, Zuliani P, Komuravelli A, Faeder JR, Clarke EM. Analysis and verification of the HMGB1 signaling pathway. BMC Bioinformatics 2010; 11(SUPPL 7): S10.